EP 27

Druggability and AI

The concept of druggability is evolving with the help of AI and new therapeutic modalities. This episode explores how science is expanding what's possible and making the process more efficient and precise. From traditional small molecules to biologics and RNA therapeutics, new approaches are being developed to tackle previously undruggable targets. AI is playing a crucial role in accelerating and improving the drug discovery process, from identifying potential targets to designing new molecules.

druggabilityAIbiologicsRNA therapeuticstargeted protein degraders

play_arrowListen to episode

Key Concepts

Druggability

The concept of druggability is evolving with the help of AI and new therapeutic modalities.
Druggability is no longer limited to traditional small molecules, but now includes biologics and RNA therapeutics.

Biologics

Monoclonal antibodies have emerged as a powerful tool for targeting specific proteins, especially those on the cell surface.
Biologics can target large, flat surfaces or complex shapes that small molecules cannot handle.

RNA Therapeutics

RNA therapeutics, such as antisense oligonucleotides and small interfering RNAs, can target specific genes and transcripts.
RNA therapeutics allow for a more precise approach to drug discovery, targeting the source of the disease rather than just the symptoms.

Targeted Protein Degraders

Targeted protein degraders, like PROTACs, can eliminate specific proteins, offering a new approach to tackling previously undruggable targets.
PROTACs work by recruiting the protein to the cell's natural protein disposal system, allowing for the degradation of the target protein.

AI in Drug Discovery

AI is accelerating and improving the drug discovery process by analyzing large amounts of biological data, predicting potential targets, and designing new molecules.
AI can predict binding affinities, design new molecules, and optimize therapeutic approaches, making it a crucial tool in modern drug discovery.

Episode Summary

check_circleThe concept of druggability is no longer static and is evolving with the help of AI and new therapeutic modalities.
check_circleTraditional small molecules had limitations in targeting certain proteins, but new modalities like biologics and RNA therapeutics are expanding the potential target space.
check_circleMonoclonal antibodies have emerged as a powerful tool for targeting specific proteins, especially those on the cell surface.
check_circleRNA therapeutics, such as antisense oligonucleotides and small interfering RNAs, can target specific genes and transcripts, allowing for a more precise approach to drug discovery.
check_circleTargeted protein degraders, like PROTACs, can eliminate specific proteins, offering a new approach to tackling previously undruggable targets.
check_circleAI is accelerating and improving the drug discovery process by analyzing large amounts of biological data, predicting potential targets, and designing new molecules.
check_circleAI can predict binding affinities, design new molecules, and optimize therapeutic approaches, making it a crucial tool in modern drug discovery.
check_circleThe integration of AI and new modalities is expanding the druggable landscape, allowing for the targeting of previously undruggable proteins and diseases.

Full Transcript

Discussion

Join the discussion — sign in to leave a comment.